rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Niki BioSolutions, Inc.

NIKI · Nasdaq

Health CareLife-science toolsNot moving yet

NIKI stood above a rising 150-day average in 2 of the last 52 weekly readings, and has been out of that trend for the last 50 weeks. It is 74.3% below that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 50
Industry in uptrend
52% +4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
0

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 2 of 52 weeks.

17 Apr – 16 Oct
26%41%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$1$0$1Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months0
Sale orders, 12 months0
Buyers · sellers0 · 0

No open-market buy or sale by its insiders on record.

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders0
New · exited0 · 0
Reported value$0

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange

Everyone who traded it

Nobody on record has traded it.

Same industry

OABI OmniAbLeading+65%
TXG 10x GenomicsLeading+60%
AVTR AvantorLeading+47%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+37%
MASS 908 DevicesLeading+31%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Share count trendFY 2025 · to 31 Dec 202534.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$3.5M

Analyst forecasts

No analyst forecasts yet.